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Neuroimaging studies of patients with treatment-resistant depression (TRD) have reported 
abnormalities in frontal and temporal regions. We sought to determine whether metabolism in 
those regions might be related to response to repetitive transcranial magnetic stimulation 
(TMS) in patients with TRD. Magnetic resonance images and baseline resting-state cerebral 
glucose uptake index (gluMI) obtained using 18F-fluorodeoxyglucose positron emission 
tomography were analyzed in TRD patients who had participated in a double-blind, 
randomized, sham-controlled trial of prefrontal 10Hz-TMS. Among the patients randomized 
to active TMS, 17 responders, defined as having 50% depression score decrease, and 14 
nonresponders were investigated for pre-stimulation glucose metabolism and compared with 
39 healthy subjects using a voxel-based analysis. In nonresponders relative to responders, 
gluMI was lower in left lateral orbitofrontal cortex (OFC), and higher in left amygdala and 
uncinate fasciculus. OFC and amygdala gluMI negatively correlated in nonresponders, 
positively correlated in responders, and did not correlate in healthy subjects. Relative to 
healthy subjects, both responders and nonresponders displayed lower gluMI in right 
dorsolateral prefrontal (DLPFC), right anterior cingulate (ACC), and left ventrolateral 
prefrontal, cortices. Additionally, nonresponders had lower gluMI in left DLPFC, ACC, left 
and right insula, and higher gluMI in left amygdala and uncus. Hypometabolisms were partly 
explained by gray matter reductions, while hypermetabolisms were unrelated to structural 
changes. The findings suggest that different patterns of frontal-temporal limbic abnormalities 
may distinguish responders and nonresponders to prefrontal magnetic stimulation. Both 
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Treatment-resistant depression (TRD) occurs in 20 to 30% of depressed patients and leads to 
severe disability (Greden, 2001). Neuroimaging studies focused on TRD patients are rare, and 
have reported decreased blood flow or glucose metabolism in prefrontal regions such as the 
anterior cingulate cortex (ACC) (Mayberg et al, 1994; 1997a; Drevets et al, 1997; Ketter et 
al, 2001; Konarski et al, 2007), and in anterior temporal cortices (Mayberg et al, 1994). 
Differential frontal-temporal changes have been reported in medication responder and 
nonresponder subgroups of depressed patients. Responders to antidepressants were found to 
have lower pre-treatment glucose metabolism in both left amygdala region and temporal 
cortex, and in bilateral frontal cortices (Little et al, 2005). In line with these findings, higher 
resting-state hippocampus-amygdala blood flow was found in a group of TRD compared with 
nonresistant patients and healthy controls (Hornig et al, 1997). Cortical-limbic balance 
involving orbitofrontal cortex (OFC), ACC, hippocampus and DLPFC might differentiate 
responders from nonresponders to antidepressant medications (Seminowicz et al, 2004). 
 
Repetitive transcranial magnetic stimulation (TMS) has been proposed as a potential 
treatment for TRD (George et al, 1995; Pascual-Leone et al, 1996) that can easily be applied 
in clinical settings and is well tolerated. This procedure aims at stimulating the left 
dorsolateral prefrontal cortex (DLPFC) in order to increase brain metabolism in prefrontal 
areas using high stimulation frequencies, above 5Hz. However, although a number of studies 
have now demonstrated the clinical effectiveness of TMS in TRD patients (Lam et al, 2008), 
the effects remain variable and factors predictive of response remain poorly understood (Loo 
and Mitchell, 2005; Herrman and Ebmeier, 2006; Lisanby et al, 2009). Since this therapy is 




or predict outcome. High-frequency TMS of prefrontal regions, as used to treat depression, 
has been shown to modulate ACC and caudate nucleus activity in healthy subjects (Barrett et 
al, 2004). In addition, blood flow decreases in OFC and ACC have been reported after 
treatment with high-frequency TMS (Nadeau et al, 2002) in responders to TMS. So far, 
however, it is not clear whether pre-stimulation functional anatomy could influence TMS 
efficacy and predict response. 
 
We a priori hypothesized that TRD patients who were nonresponders to TMS would have 
specific alterations in those frontal-temporal-limbic regions involved in TRD and in TMS 
effects, and also in the uncinate fasciculus a frontal-temporal fiber tract that we have reported 
to be altered in patients with affective disorders (Houenou et al, 2007). We used [18F]-
fluorodeoxyglucose positron emission tomography ([18F]-FDG-PET) to determine whether 
resting functional brain characteristics at baseline could differentiate responders from 
nonresponders to 10Hz-TMS in a group of TRD patients. Additionally, we searched for a 
potential influence of structural anatomy on metabolism, and for functional correlations 
within the regions involved in response to TMS. 
 
SUBJECTS AND METHODS 
 
The investigation was performed in accordance with the Declaration of Helsinki. The study 
was approved by the ethics committee Ile-de-France 6, Paris. Written informed consent was 







Pre-trial PET and MRI data from the 34 patients who were initially randomized to an active 
arm in a double-blind, sham-controlled trial of 10Hz-TMS including 48 patients (Paillère 
Martinot et al, 2009) were considered for the present imaging study. The patients had a DSM-
IV-TR diagnosis of Major Depressive Disorder established by clinical interview using the 
Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al, 1998), with criteria for 
treatment resistance to at least two trials of antidepressants of different classes given at 
adequate doses (above 150 mg/day in an equivalent dose of imipramine) and duration (at least 
four weeks for each drug).  
 
Exclusion criteria included age over 65, pregnancy, alcohol or substance dependence in the 
past 6 months, electroconvulsive therapy (ECT) treatment in the past 6 months, any present 
medical condition, history of epileptic seizures, history of neurological disorders or 
substantial brain damage, and contraindication to magnetic fields. On examination of the 
patient medical charts, three patients were excluded, due to past early-onset alcoholism in 2 
patients, and to a possible diagnosis of fibromyalgia in one patient. Indeed, alcoholism with 
onset in adolescence might have modified brain structure (Chanraud et al, 2007), and 
fibromyalgia has been reported to alter brain activity in fronto-cingulate areas (Burgmer et al, 
2009).  
 
Thus, data from 31 patients were analyzed in the present study (mean (SD) age=47.7 (7.3); 
range: 30.5-59.5, 20 women). They had on average 7.4 (4.4) years of education after primary 





Thirty-nine paid healthy comparison subjects with no personal or family history of psychiatric 
or neurologic disorder, as assessed by a medical examination, were recruited by word of 
mouth from community volunteers during the same time period (age: mean(SD) =45.2(11.8); 
range: 25-62, 25 women; years of education after primary school: mean (SD)=9.10 (4.8) ). 
Patients and healthy subjects did not differ in age (t=0.99, df=68, p=0.32), gender (χ2 
test=0.000, p=0.98), years of education (t=1.53, df=67, p =0.13), or Annett’s (1970) laterality 




Design. The stimulation procedure and determination of PET-derived targets for TMS have 
been described elsewhere (Paillère Martinot et al, 2009). Briefly, after scanning, the patients 
were randomized to treatment with PET-guided, active-standard or sham-standard TMS and 
subsequently underwent 10 sessions of 10 Hz-TMS delivered at 90% motor threshold with 
1600 pulses/session, using a Magstim super-rapid® device with active and sham air-cooled 
figure-of-eight coils (Magstim Co., Withland, Dyfed, UK). Guided TMS was on a prefrontal 
target determined with FDG-PET. Standard stimulation was as usual left pre-frontal, 5cm 
anterior to the hotspot of the hand motor cortical region. Patients and raters were blind to 
TMS modality. 
 
Treatment allocation.The 31 patients in this imaging study had been randomly allocated to 
standard TMS (n=9 in responder group, n=6 in nonresponder group), or to PET-guided TMS 
(n=8 in responders, n=8 in nonresponders (Table 1). No difference in allocation was found 
across groups (χ2= 0.31, df=1, p=0.56). No patient randomized to sham TMS was analyzed in 




response to active treatment, and as there were only 3 responders out of 14 sham-treated 




Baseline assessment was performed on the day before scanning using the Montgomery-
Åsberg Depression Rating Scale (MADRS)(Montgomery and Asberg, 1979), the 21-item 
Hamilton Depression Rating Scale (Ham-D) (Hamilton, 1960), and the Tyrer anxiety scale 
(Tyrer et al, 1984). 
 
Response to TMS, defined as at least 50% decrease from baseline MADRS score, as in 
another TMS study of depressed patients (O’Reardon et al, 2007), was assessed using the last 
clinical assessment performed just after the final TMS session. Among the actively-treated 




Previous medication was titrated down to a minimal dose that did not lead to significant 
clinical worsening for at least two weeks before scanning. Five responders and 4 
nonresponders had a stage II resistance (failure to at least two adequate trials of 
antidepressants), according to Thase and Rush criteria (Thase and Rush, 1997), 9 responders 
and 5 nonresponders a stage III (stage II and failure to tricyclics), 2 responders and 5 
nonresponders a stage IV (stage III and failure to monoamine oxidase inhibitors (MAOI)), 
and one patient had a stage V resistance (stage IV and ECT resistance) in the responder to 







Seven patients met criteria for a comorbid diagnosis of anxiety disorder (panic disorder with 
or without agoraphobia, or generalized anxiety disorder); eleven patients had resistant 
depression in the course of bipolar disorder. Among the latter patients, 3 had a bipolar II type 
disorder, all of which were in the nonresponder group. Those comorbid diagnoses were 




All participants were investigated at rest. They were instructed to lie and relax in the PET 
camera with eyes closed, in a quiet room with low dimmed light. Head movement was 
restricted with an individually molded thermoplastic mask.  
 
[18F]-FDG-PET 3D-images were obtained following a transmission scan for attenuation 
correction, from a Siemens-ECAT-EXACT-HR+ tomograph which collects 63 simultaneous 
slices (intrinsic in-plane resolution: 4.3mm; voxel size: 2.42×2.42×2.43 mm3). A summed 
image corresponding to the attenuation- and decay- corrected uptake of the [18F]-FDG, 
expressed in activity concentration (Bq/cc), was obtained from two 3D-time-frames (ten 
minutes each) collected 30 to 50 min after intraveinous injection of the radioligand. The mean 
(SD) injected 18F-fluorodeoxyglucose radioactivity was 155.6 (9.25) MBq in the patients (see 






3D Structural Magnetic resonance images (MRI) were acquired on a 1.5 Tesla GE Signa 
scanner (General Electrics Medical Systems, Milwaukee, WI, USA) using a T1-weighted 
spoiled gradient recalled sequence (124 contiguous slices; field of view 24cm; 256x256 
matrix; voxel size: 0.94×0.94×1.3 mm3). 
 




All of the [18F]-FDG-PET and structural images were processed with Statistical Parametric 
Mapping software package (SPM5, Wellcome Department of Cognitive Neurology, 
University College, London, UK; http://www.fil.ion.ucl.ac.uk/spm), implemented on 
Matlab® (The Mathworks, Natik, Massachusetts; http://www.mathworks.com).  
 
Structural pre-processing. To take into account a possible effect of structure on [18F]-FDG 
images, voxel-based morphometry (VBM) was performed using the unified segmentation 
implemented in SPM5 (Ashburner and Friston, 2005). T1-weighted images were spatially 
normalized, segmented into gray and white matter and modulated before being smoothed with 
a 10 mm full-width half-maximum (FWHM) isotropic gaussian kernel.  
 
[18F]-FDG-PET pre-processing. For the healthy subject group, each [18F]-FDG image was 
coregistered to its corresponding T1-weighted image using a rigid-body model. 
Transformation matrices obtained during the spatial normalization of the T1-weighted images 
to the MNI template were then applied to the resulting [18F]-FDG images. The mean image of 




smoothed with an 8 mm FWHM isotropic gaussian kernel. Finally, all subjects [18F]-FDG 
images were spatially normalized to this template and smoothed with an 8 mm FWHM 




Demographic and Clinical data. Analyses were performed using JMP®8 software from SAS 
(SAS institute inc., SAS campus drive, Cary, North Carolina, USA). Unpaired t-tests and χ2 
tests were used for comparing continuous and categorical variables, respectively, in between-
group comparisons. Statistical significance was defined as p<0.05, two-tailed. 
 
Image analysis. Voxel-wise comparisons were performed using SPM5 within the framework 
of the General Linear Model (GLM). All results were obtained within the mask of the 
hypothesized regions of interest, drawn using Wake Forest University (WFU) PickAtlas 
(Maldjian et al, 2003), including inferior frontal, middle frontal, superior frontal, medial 
frontal, and orbital gyri, ACC, inferior temporal and parahippocampal gyri, insula, amygdala, 
caudate, and “extra-nuclear” fiber tracts. Brain locations were reported as x, y, and z 
coordinates in Montreal Neurologic Institute (MNI) space and WFU PickAtlas was used to 
convert MNI coordinates into Talairach coordinates. The Talairach and Tournoux atlas 
(Talairach and Tournoux, 1988) was used to identify brain regions and approximate 
Brodmann areas (BA). 
 
MRI image analysis. Group comparisons of structural images were performed on gray matter 
and white matter tissues using an analysis of covariance (ANCOVA) with group 




total intracranial volume as confounding covariates. An F-test was used to compare the 3 
groups. Significance threshold was set at p<0.05, False Discovery Rate (FDR) corrected for 
multiple comparisons. 
 
PET image analysis. [18F]-FDG 3D-images were entered into the General Linear Model 
within SPM5; in order to control for global glucose uptake effects we used proportional 
scaling global normalization, yielding an index of regional- relative to global- glucose uptake 
(gluMI). Baseline gluMI were compared between responder, nonresponder patients, and 
healthy subjects using an ANCOVA with group as between-subject factor and age and gender 
as confounding covariates. An F-test was used to compare the 3 groups. Significance 
threshold was set at p<0.05, False Discovery Rate (FDR) corrected for multiple comparisons. 
Thereafter, post-hoc t-tests were performed within the regions where the F-test was 
significant. The “healthy group versus responders”, “healthy group versus nonresponders”, 
and the “responders versus nonresponders” contrasts were examined. Significance was set at 
p<0.001, uncorrected. Cluster significance thresholds (extent threshold) were set at 10 
contiguous voxels (voxel size = 8 mm3) to reduce type I errors introduced by potential noise.  
 
PET-MRI analysis. Relations between gluMI and structure were assessed using the Biological 
Parametric Mapping (BPM) toolbox (Casanova et al, 2007). BPM combines information from 
different imaging modalities on a voxel-wise basis using the GLM. Imaging variables are 
integrated on a voxel-wise basis, so each voxel has a unique regression design that includes 
the value of each imaging modality for that voxel. Group comparisons of regional cerebral 
gluMI after accounting for volumetric changes were performed using an ANCOVA with 
group as between-subject factor, age and gender as basic confounding covariates, and 




the same regions where the F-test of the PET analysis was significant. The “healthy group 
versus responders”, “healthy group versus nonresponders”, and the “responders versus 
nonresponders” contrasts were examined. Significance was set at p<0.001, uncorrected. 
Cluster significance thresholds (extent threshold) were set at 10 contiguous voxels (voxel size 
= 8 mm3). 
 
Correlation analyses. In order to explore the relationships between gluMI in different regions 
(PET regional correlations) or between gluMI and clinical scores (PET-clinical symptoms 
correlations), individual gluMI values at significant peak-voxels were extracted from the SPM 
F-map. Correlation analyses were performed with JMP®8. All correlations were examined 
using ANCOVAs with group as between-subject factor.  
 
 
As our aim was to examine intergroup differences, we report herein the interaction effects 
between groups and correlations. Significance was set at p<0.05 Bonferroni corrected, for all 
ANCOVAs. Post-hoc correlations were performed in each group using Pearson’s r test, when 




Demographic, clinical and treatment characteristics of the patients 
 
Responders to TMS did not differ from nonresponders with regard to clinical symptoms at 
baseline, disease history, comorbidities, family history of depression, TMS parameters, type 




benzodiazepines or ECT prescriptions. No difference was found between subgroups regarding 
the resistance stage (χ2 = 1.48, df=2, p=0.48) (Table 1 and table S1). 
 
Additionally, bipolar (BP) and unipolar (UP) TRD patients did not differ regarding age (BP: 
mean age(SD)= 47(5.9), UP: mean age(SD)= 47.8(8.1),  Student’s t test score=0.27, df=29, 
p=0.79), gender (BP:6 women, 5 men, UP: 14 women,6 men, χ2 =0.73, df=1, p=0.39), age at 
onset (BP: 26.3(7.7), UP: 29.3(10.8), t score=0.82, df=28, p=0.42), duration of illness (BP: 
20.7(7.3)years, UP: 18.2(10.0)y, t score= 0.73, df=28, p=0.47), duration of depressive episode 
(BP: 3.4 (3.3)y, UP: 2.7(1.8)y, t score=0.77, df=28, p=0.44), number of depressive episodes 
(BP: 4.2(1.9), UP: 3.4(1.8),  t score=1.07, df=27, p=0.29), or family history (BP: yes=4, UP: 
yes=10, χ2 =0.54, df=1, p=0.46). UP and BP did not differ in depression scores improvement 




There was a main effect of group on the [18F]-FDG-PET images before accounting for 
structural differences, as evidenced by the results of the F-test, which revealed a pattern of 
several regions (Table 2). Post-hoc t-tests performed in those regions showed that both 
responders and nonresponders to TMS had, in comparison with healthy subjects, lower 
prefrontal gluMI in right ACC, right DLPFC, and left ventrolateral prefrontal (VLPFC) 
cortex. Additionally, nonresponders had lower gluMI in left ACC, left DLPFC, right and left 
anterior insula, and left OFC. They also displayed higher gluMI in left inferior temporal-
limbic regions including uncus, left amygdala, and left uncinate fasciculus. No significantly 




nonresponders relative to responders, gluMI was higher in the left amygdala, uncinate 
fasciculus and anterior commissure, and lower in the left OFC (Table 2, Figure 1).  
 
MRI corrected PET findings 
 
When accounting for volume differences, regions that survived the volume correction 
included right ACC, right and left insula, left DLPFC, left uncus at BA20, and left amygdala 
(Table 2). Volume fully accounted for lower gluMI in the left OFC, left VLPFC (BA9/47), 
left ACC and right DLPFC. Higher gluMI was not related to white matter volume in uncinate 




Voxel-based comparison of the GM maps revealed no main effect of group at the p<0.05 FDR 
corrected for multiple comparisons. However, at a more permissive threshold GM volume 
reductions were observed in some regions where gluMI was low, including the left OFC 
(BA10, t=3.52, p<.001 unc, k=36 voxels) in nonresponders relative to responders and relative 
to healthy subjects (t =2.87, p <.002, k=312 voxels), and in the left ACC (BA 32, t =3.40, p 
<.001 unc, k=46) in nonresponders relative to healthy subjects. No regional difference was 
found in white matter maps between responders, nonresponders and healthy subjects. 
 
FDG -PET Regional Correlations  
 
Responders, nonresponders, and healthy subjects significantly differed in several PET 





Interactions (F-tests). Significant interactions (gluMI X group) were found between left OFC 
and several regions in which metabolic level was independent of structure. Regions included 
left amygdala (F=8.20, df=2), left DLPFC at BA9 (F=11.79, df=2), left VLPFC at BA9 
(F=14.34, df=2), right ACC (F=8.18, df=2), and left uncus (BA20) (F=8.31, df=2).  
 
Post-hocs tests (Table 3). In the nonresponders, left amygdala gluMI was negatively 
correlated with gluMI in the left OFC, while a positive correlation in the responders and no 
correlation in the healthy subjects was observed (Figure 2). A negative correlation was also 
found in nonresponders between gluMI in left uncus and left OFC, but no correlation was 
found in responders or in healthy subjects. Positive correlations were observed in 
nonresponders, but not in other groups, between OFC and 1/ prefrontal regions including left 




No significant interaction (gluMI X group) was found between gluMI and baseline scores of 




Pre-treatment brain glucose metabolism at rest and regional volumes were investigated in 
patients with resistant depression to assess whether these characteristics could differentiate 
responders and nonresponders to prefrontal TMS. Nonresponders had a pattern of widespread 




Low metabolism was related to variations in GM volume in several regions, notably in left 
OFC and ACC where lower GM volume was observed in nonresponders. Uniquely, different 
correlations between left amygdala and left OFC metabolism distinguished the nonresponders, 
responders and healthy subject groups.  
 
Functional correlates of response to TMS 
 
Few studies have examined brain correlates of antidepressant response to high-frequency 
TMS and most of those studies have used single photon emission computerized tomography 
(SPECT) in smaller groups of patients, pooling both medication-resistant and nonresistant 
depressed patients, with response defined as a 30% decrease in depression scores (50% in the 
present study). Responders to TMS have been found to have higher blood flow in inferior 
frontal lobe before stimulation (Teneback et al, 1999), or lower blood flow in amygdala 
(Nadeau et al, 2002) than nonresponders, consistently with our results. Improvement in 
depression scores with TMS has also been found to positively correlate with blood flow in the 
anterior cingulate (Langguth et al, 2007) and in the right peri-insular region (Mottaghy et al, 
2002).  
 
Consistently with other studies of TRD patients (Videbech, 2000; Konarski et al, 2007), the 
present findings point to a pattern of decreased prefrontal glucose metabolism, particularly in 
regions involved in TMS response, including the insula, the ACC and the OFC. In 
nonresponders to TMS relative to responders, low glucose metabolism was observed in those 
regions, and related to lower GM volumes in the left ACC and in the rostral part of the left 
OFC. In line with this finding, hypometabolism in OFC has been hypothesized to be related to 




(Drevets, 1999), while normal glucose metabolism in OFC has been reported in medication-
resistant depressives with no GM reduction (Drevets, 2000; Drevets et al, 2002). Thus, the 
present results support that OFC gray matter volume reduction might precondition a negative 
response to prefrontal TMS.  
 
A functional pattern of prefrontal hypometabolism associated with temporal limbic 
hypermetabolism has previously been reported in various groups of depressed patients 
regardless of resistance to treatment (Konarski et al 2007; Brooks et al, 2009; Savitz and 
Drevets, 2009). In the present study, a functional amygdala hypermetabolism was only 
observed in the TRD nonresponders to TMS, regardless of GM volume. Thus, the present 
findings raise the hypothesis that high metabolic levels of the temporal-limbic regions, 
particularly the amygdala, might precondition non response to prefrontal TMS.  
 
Frontal-limbic correlations in resistant depressives 
 
Distinct correlations were found between OFC and the amygdala in nonresponders, 
responders, and healthy subjects, indicating different frontal-limbic relations depending on the 
group. The OFC is involved in coding of the identity of the sensory stimuli and their 
rewarding properties (Schultz et al, 1998), and is connected with the lateral nuclei of the 
amygdala, which activity appears closely related to the context and level of aversiveness of 
the stimuli (Zald, 2003). Through inhibitory projections to the amygdala, the lateral OFC is 
consequently involved in controlling information processing, particularly representation of 
rewards and punishments, and regulates behavior expression and emotional responses 
(Hooker and Knight, 2006). Thus, GM reductions in this region may disturb interactions 




as the cingulate cortex or the striatum. Our findings are consistent with a frontal-limbic 
dysregulation in the subgroup of nonresponders leading to decreased frontal cortical 
regulation of temporal limbic activation in response to negative stimuli, as has previously 
been hypothesized in TRD (Mayberg, 1997b). In those patients, and as prefrontal TMS seems 
to modulate OFC activity (Nadeau et al , 2002), GM reduction of the OFC might partly 
account for the observed specific resistance to TMS. Such resistance to TMS in those patients 
may additionally be related to altered white matter tracts in the ventral frontal-temporal limbic 
network. Indeed, higher glucose metabolism was detected in left uncinate fasciculus and 
anterior commissure in nonresponders, independently of white matter volumes. As pointed 
out by Buschbaum and coworkers (2007), the increased metabolism might reflect increased 
energy need due to defects in white matter, which in turn, may lead to inefficiency in brain 
circuitry. The uncinate fasciculus is a bidirectional pathway that links the anterior temporal 
lobe and amygdala with the medial and orbital prefrontal cortices, and the anterior 
commissure is a fiber bundle that connects the inferior temporal with sites including the 
amygdala and orbitofrontal cortex (Schmahmann and Pandya, 2006). Thus, it can be 
speculated that, due to changes in the OFC/VLPFC, and connecting white matter tracts such 
as the uncinate fasciculus, TMS would fail to modulate the prefrontal cortex and temporal-




First, while there is no larger FDG-PET study associated with a controlled TMS trial, the 
short treatment duration might be seen as a limitation.  Indeed, TMS has been found to be 
more effective with longer treatment durations (O’reardon et al, 2007). Thus, some 




over a longer period of time. However, despite the small number of subjects and short 
treatment duration, the results of the clinical trial (Paillère Martinot et al, 2009) showed that 
the chosen protocol accelerated the effect of TMS, with a strong effect size (Cohen’s d=0.78; 
Cohen, 1988) over sham stimulation, probably accounting for the high response rate in the 
study.  
 
A second limitation relates to previous medication. It was not possible to withdraw all 
treatments in those difficult patients, and it was not possible to assess all the dosages 
prescribed along their illness as they had very long illness durations. However, antidepressant 
and mood stabilizers were prescribed in usual standard dosages in all the patients. Effects of 
medication on FDG measures have been studied in a few studies, with inconsistent results. 
Apparently, brain metabolic responses to antidepressants vary according to the underlying 
physiopathology of the patient and the degree of symptomatic improvement (Saxena et al, 
2002), and chronic antidepressant drug treatment might reduce metabolism in the amygdala 
and ventral ACC in depressed subjects showing a positive treatment response only (Drevets et 
al, 2002). Here, the patients were all similarly resistant to medication according to Thase and 
Rush criteria, and the number of patients on antidepressants and duration of illness or episode 
were comparable across groups. Also, the number of patients on antipsychotics and the 
dosages were very small and similar in both patient groups, as was the number of patients on 
mood stabilizers; thus, it is unlikely that their effect would have confounded the metabolic 
findings. Finally, most patients were on low doses of benzodiazepines, which have been 
reported to induce decreases in glucose metabolic rates in regions such as the basal ganglia, 
thalamus or visual cortex (Martinot, 1992). These effects might have blurred some differences 
with the comparison subjects, but as the patients’ prescriptions did not differ across 




comparison of responders with nonresponders. Moreover, the metabolic findings are 
consistent with findings of other studies of untreated depressed patients (Teneback et al, 
1999). 
 
Third, in a few studies, resistance to TMS has been associated with previous medication 
resistance, or anxiety comorbidity (Fregni et al, 2006; Brakemeier et al, 2008; Lisanby et al, 
2009). In this study, medication resistance was comparable across responders and 
nonresponders to TMS. Regarding comorbid anxiety, the number of patients with a comorbid 
anxiety disorder was similar in both groups, and anxiety scores before scanning were similar 
across groups, and did not correlate with PET measures, which suggests that nonresponse 
parameters did not depend on anxiety comorbidity in this group.  
 
Fourth, the pooling of patients with unipolar resistant depression and with resistant depression 
in the context of history of bipolar disorder may be considered as a limitation. At variance 
with most previous reports, the present study aimed at assessing [18F]-FDG in highly 
treatment-resistant patients notwithstanding the UP/BP dichotomy, rather than to compare UP 
or BP subgroups. In addition, many imaging studies indicate increased resting state 
metabolism in the amygdala in Major Depressive Disorder as well as in BP depression (Savitz 
and Drevets, 2009). Regarding orbitofrontal cortex, resting state activity has generally been 
found similarly increased both in UP and BP depressives (Drevets, 2000), though in more 
severely ill or TRD patients, studies have found no change or decreased function (Mayberg et 
al., 1994;  Savitz & Drevets, 2009). Thus, putative differences in functional pattern reported 
in the literature between BP and UP patients are not clear-cut.  
In addition in the present study, the UP/BP ratios were similar in both responders and 




improvement rates or depression history, or when comparing UP and BP groups using a 
similar image analysis, within the same regions of interest and at the same statistical threshold 
as in the responder/nonresponder analysis. Regarding the responder/nonresponder 
comparisons, and although the groups were much smaller, the same left amygdala function 
and left OFC gray matter pattern still distinguished responders from non responders within 
each subgroup. Both in the BP and in UP the subgroups nonresponders had significantly 
higher amygdala gluMI (Wilcoxon test, BP: responders, mean(SD)=-1.36 (1.86), 
nonresponders mean(SD)=9.49 (2.04), χ2=5.63, p=0.02; UP: responders, mean(SD)=-2.19 
(1.65), nonresponders mean(SD)=5.21 (1.82), χ2=6.48, p=0.01). Similarly, BP and UP 
nonresponders had significantly lower GM in OFC than their responder counterparts 
(Wilcoxon test, BP: responders, mean(SD)=0.04 (0.02), nonresponders mean(SD)=-0.03 
(0.02), χ2=5.63, p=0.02;  UP: responders, mean(SD)=0.01 (0.01), nonresponders mean(SD)=-
0.04 (0.02), χ2= 5.73, p=0.02). In addition, the differential relation between amygdala and 
OFC gluMI according to treatment response (responders, nonresponders) was maintained in 
both the UP and BP diagnostic subgroups (gluMI x group interactions, UP: t = 2.13, p= 0.05; 
BP: t= 2.40; p= 0.05).  
 
In summary, the results suggest that alterations in brain metabolism and structure influence 
the response to TMS. Response to prefrontal TMS might depend on orbitofrontal cortex 
volume and amygdala functioning. Further research is needed to determine the predictive 
value of such a functional pattern determined at an individual level in patients with resistant 
depression referred to TMS therapy. 
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TITLES AND LEGENDS TO FIGURES 
 
Figure 1: Top, left frontal view: Main comparison (F-test) between responders, 
nonresponders and healthy subjects. Height threshold: p<0.05, false discovery rate corrected, 
extent threshold: 10 voxels (A). Bottom, lateral views: T-maps of baseline regional cerebral 
glucose metabolism index (gluMI) in 17 responders to rTMS (B, left) and in 14 non 
responders (C, right) compared with 39 healthy subjects, respectively (Height threshold: 
p<0.001, extent threshold: 10 voxels); Red color indicates higher gluMI, blue indicates lower 
gluMI. Statistical maps are projected on a normalized brain mesh.  
 
Figure 2: Regional correlations between regional cerebral glucose metabolism index in left 
frontal BA10 at MNI coordinates (x=-32, y=50, z=-4) and in left amygdala at (x=-24, y=-2, 
z=-28). Interaction: F=8.20, df=2, p<0.001. Red: negative correlation in nonresponders, 
Pearson's r=-0.55, p=0.042. Blue: positive correlation in responders, Pearson's r=0.52, 















Gender (M/F), n 6/11 5/9 .98 
Age, y, mean(SD) 48.7(6.2) 46.4(8.6) .40 
Education, y2, mean(SD) 7.1(4.6) 7.8(4.3) .69 
Annett scale Laterality score, mean(SD) 75.9(64.5) 98.5(3.2) .22 
Age at onset, y, mean(SD) 30.1(10.9) 26.1(8.2) .27 
Duration of illness, y, mean(SD) 18.2(10.9) 20.1(6.6) .58 
Duration of episode, y, mean(SD) 3.6(2.7) 2.1(1.7) .10 
Family depression, n(%) 9 (53) 5 (36) .34 
Bipolar resistant depression, n(%) 6 (35) 5 (36) .98 
Number of depressive episodes, mean(SD) 3.3(1.6) 4.07(2.09) .30 
Number of manic episodes, mean(SD) 0.6(1.2) 0.4(0.8) .44 
Comorbid Anxiety Disorder, n(%) 3 (18) 4 (29) .47 
Tyrer anxiety scale score, mean(SD) 20.2(1.8) 20.7(2.1) .87 
Left guided/ Right guided/Left standard rTMS, n 6/2/9 3/5/6 .26 
18FDG dose, Mbq, mean(SD) 154.1 (7.6) 157.3 (10.8) .36 
MADRS scores, mean(SD)    
Baseline 32.1(7.7) 35.1(6.3) .26 
End-point 8.9(4.0) 27.6(9.0) <.001 
%improvement 71.0(12.8) 21.5(20.2) <.001 
HDRS scores, mean(SD)    
Baseline 25.2(4.5) 26.7(5.7) .41 
End-point 9.0(3.3) 21.6(6.8) <.001 
%improvement 63.7(12.2) 19.0(16.1) <.001 
Ongoing medications, n(%)    
Antidepressants 8(47) 6(43) .81 
Mood stabilizers 5 (29) 6 (43) .48 
Antipsychotics 7 (41) 7 (50) .37 
Benzodiazepines 7 (41) 8 (57) .28 
Past medications, n(%)    
Antidepressants 17(100) 14(100) >.99 
Mood stabilizers 9 (53) 9 (64) .72 
Antipsychotics 8 (47) 10 (71) .27 
Benzodiazepines 11 (65) 11 (78) .46 
ECT 6(35) 7 (50) .92 
  
 
Abbreviations: rTMS, repetitive transcranial magnetic stimulation; MADRS, Montgomery & Äsberg Depression 
Rating Scale; HDRS, Hamilton depression rating scale, 21 items;18FDG, 18 fluorodeoxyglucose; ECT, 
electroconvulsive therapy. 
1 χ2 tests, Fisher exact tests, and t tests were used when appropriate. All statistics were two-tailed 





Table 2. Differences in regional cerebral glucose metabolism index between 17 responders and 14 nonresponders  to rTMS compared with 39 
healthy subjects 
 
 Main effect of group1 Group Comparison, t value 2 Volume corr. 6,  t value 2
Brain Region BA Cluster 
Size3,4 




R<HS NR<HS NR>HS R>NR R<NR R<HS NR<HS NR>HS R<NR
Right MFG 9 317 34 12 38 11.42 3.55 4.14 … … … … … … … 
Right Insula 45 191 36 22 12 9.75 … 3.97 … … … … 3.25 … … 
Right ACC 32 850 12  34   22 13.67 3.37 4.85 … … … 3.56 4.22 … … 
Left ACC 32 … -2 38 28 9.03 … 4.07 … … … … …. … … 
Left MFG 9 26 -40 28 42 7.86 … 3.93 … … … … 3.53 … … 
Left IFG 9 630 -40 8 38 9.86 3.49 3.84 … … … 3.32 … … … 
Left IFG 47 … -48 14 24 9.60 4.10 3.46 … … … 3.57 … … … 
Left MFG  46 … -44 26 26 9.52 … 4.18 … … … 3.32 3.43 … … 
Left MFG 
(Orbital) 
10 43 -32 50 -4 8.17 … 3.94 … 3.79 … … … … … 
Left insula 45 60 -32 26 8 8.28 … 3.80 … … … 3.77 3.22 … … 
Left Amygdala … 439 -24 -2 -28 13.10 … … 4.84 … 4.60 … … 4.79 4.57 
Left ITG (Uncus) 20 … -32 -10 -38 8.82 … … 4.20 … … … …. 4.33 … 
Left UF … 93 -32 4 -10 8.41 … … 3.60 … 3.87 … … 3.51 3.80 




Abbreviations: R, responders; NR, nonresponders; HS, healthy subjects; BA, Brodmann’s area, ACC; anterior cingulate cortex; MFG, middle frontal gyrus; IFG, inferior frontal 
gyrus; ITG, inferior temporal gyrus; UF, uncinate fasciculus; AC, anterior commissure; ellipses, no cluster retrieved by comparison, or not applicable. 
1Statistics at voxel-level (F-test, df=2, 65), corresponding to a minimum corrected threshold of p< .05 False Discovery Rate (FDR) corrected, with Height threshold F=6.97, and 
Extent threshold k=10 voxels 
2Post-hoc test, Height threshold was set at p<0.001, uncorrected, and extent threshold was set at 10 voxels 
3Empty cells indicate that the region is included in the same cluster as the region immediately above 
4Cluster size is expressed in number of voxels, with voxel size=8mm3 
5Montreal Neurological Institute, in millimeters, for significant peak-voxels 




Healthy subjects (N=39) Responders (N=17) Nonresponders (N=14)
Right ACC (BA32) r=0.31; p=.06 r=-0.19; p=.47 r=0.77; p=.001
Left MFG (BA 9) r=0.19; p=.25 r=-0.20; p=.45 r=0.92; p<.001
Left IFG (BA 9) r=0.04; p=.25 r=0.02;p=.45 r=0.92; p<.0001
Left Uncus(BA20) r=0.02; p=.92 r=0.14; p=.58 r=-0.70; p=.005
Left amygdala r=0.07; p=.68 r=0.52; p=.03 r=-0.55; p=.04
Abbreviations: BA, Brodmann area; ACC, anterior cingulate cortex; MFG, middle frontal gyrus; IFG, inferior frontal gyrus; r, Pearson's correlation coefficient; p, probability value
Significant correlations are indicated in bold
Table 3: Regional correlations of glucose metabolism with orbitofrontal cortex across groups


